Structural studies on an aminopeptidase inside the endoplasmic reticulum
Project Number5R03AI078134-02
Contact PI/Project LeaderGUO, HWAI-CHEN
Awardee OrganizationBOSTON UNIVERSITY MEDICAL CAMPUS
Description
Abstract Text
DESCRIPTION (provided by applicant): Antigen processing is an integral part of cell-mediated immune surveillance and responses that involve MHC- restriction and T cell recognition. Processed antigenic peptides, when presented on cell surface by MHC molecules to T cells, serve as identity tags to be monitored by our immune system. Thus antigen processing and presentation influence the response of an individual to infectious organisms and has been implicated in the susceptibility to diseases and to the development of autoimmunity. One effective way the immune system eliminates virus-infected or malignant cells is to mount a cytotoxic reaction that result in lysis of target cells. This antiviral mechanism generally involves MHC class I molecules to bind peptides processed from viral proteins synthesized within infected cells, and present those foreign antigenic peptides to cytotoxic T lymphocytes (CTLs), which can eliminate virus-infected self-cells and thus eliminate potential sources of new viral production. Therefore, understanding the mechanisms of antigen processing is critical to fight against various pathogens. For an epitope to be recognized by T cells, foreign antigens need to be cut into short peptides with proper sizes in order to form physical complexes with MHC molecules. The precursors of class I antigenic peptides are generated mainly by proteasomes in the cytosol, and are then transported into the lumen of the endoplasmic reticulum (ER) by transporters associated with antigen processing (TAP). Recently, an aminopeptidase inside the ER, named ERAP1, has been identified to be one missing link that trims peptide precursors and generates the final N-termini of class I-restricted epitopes. Our recent success in expressing and purifying active ERAP1, and obtaining crystals of its C-terminal domain (C-dom) in the preliminary crystallization screens, have brought about the exciting possibility of providing high-resolution structural information for this critical enzyme. In this Small Research Project (R03) application, we propose to purify crystallographic quality and quantity of ERAP1 C-dom and complexes for biochemical characterization and high-resolution crystal structure determination. PUBLIC HEALTH RELEVANCE: Crystallographic quality and quantity of ERAP1 C-dom, N-dom, and full-length protein obtained in this proposal will enable biochemical and structural studies of ERAP1 to enhance our understanding of the mechanisms of antigen processing. This information is necessary for the development of protective strategies for biodefense and is thus critical to public health.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
604483045
UEI
FBYMGMHW4X95
Project Start Date
01-July-2008
Project End Date
30-June-2011
Budget Start Date
01-July-2009
Budget End Date
30-June-2011
Project Funding Information for 2009
Total Funding
$81,250
Direct Costs
$50,000
Indirect Costs
$31,250
Year
Funding IC
FY Total Cost by IC
2009
National Institute of Allergy and Infectious Diseases
$81,250
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R03AI078134-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R03AI078134-02
Patents
No Patents information available for 5R03AI078134-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R03AI078134-02
Clinical Studies
No Clinical Studies information available for 5R03AI078134-02
News and More
Related News Releases
No news release information available for 5R03AI078134-02
History
No Historical information available for 5R03AI078134-02
Similar Projects
No Similar Projects information available for 5R03AI078134-02